fh1 small molecule Search Results


fh1 small molecule  (AbMole Bioscience)
90
AbMole Bioscience fh1 small molecule
Fh1 Small Molecule, supplied by AbMole Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fh1+small+molecule/pm40346964-62-85-86?v=AbMole+Bioscience
Average 90 stars, based on 1 article reviews
fh1 small molecule - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
small molecule fh1  (ApexBio)
90
ApexBio small molecule fh1
Differentiated hepatic cells were long maintained to support a long-term genotype C HBV infection. (A) Fold changes of the mRNA levels of the human hepatic specific genes in hiPSC-HLCs treated with <t>FH1</t> as compared to that untreated after being normalized to GAPDH ( n = 6). The primers were as shown in Supplementary Table . (B) FACS analysis for the positive ratio of the hepatic specific genes in hiPSC-HLCs treated with FH1 as compared to that untreated ( n = 6). (C) Protein levels of hALB, HBV DNA, HBsAg, and HBeAg in the supernatant, and (D) intracellular HBV RNA and cccDNA of HBV-infected hiPSC-HLCs at different time points (MOI = 200, n = 6). (E) Schematic design of the in vitro ETV, RNAi, PA452, genistein, and Myrcludex B treatments from days 10 to 20 after HBV infection. (F) Detection of relative HBV infection marker suppression of the indicated antivirals at 10 days after treatment ( n = 6). S/CO, signal-to-cutoff. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.
Small Molecule Fh1, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fh1+small+molecule/pmc05952038-32-35-38?v=ApexBio
Average 90 stars, based on 1 article reviews
small molecule fh1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Differentiated hepatic cells were long maintained to support a long-term genotype C HBV infection. (A) Fold changes of the mRNA levels of the human hepatic specific genes in hiPSC-HLCs treated with FH1 as compared to that untreated after being normalized to GAPDH ( n = 6). The primers were as shown in Supplementary Table . (B) FACS analysis for the positive ratio of the hepatic specific genes in hiPSC-HLCs treated with FH1 as compared to that untreated ( n = 6). (C) Protein levels of hALB, HBV DNA, HBsAg, and HBeAg in the supernatant, and (D) intracellular HBV RNA and cccDNA of HBV-infected hiPSC-HLCs at different time points (MOI = 200, n = 6). (E) Schematic design of the in vitro ETV, RNAi, PA452, genistein, and Myrcludex B treatments from days 10 to 20 after HBV infection. (F) Detection of relative HBV infection marker suppression of the indicated antivirals at 10 days after treatment ( n = 6). S/CO, signal-to-cutoff. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Journal: Frontiers in Microbiology

Article Title: A Chimeric Humanized Mouse Model by Engrafting the Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cell for the Chronic Hepatitis B Virus Infection

doi: 10.3389/fmicb.2018.00908

Figure Lengend Snippet: Differentiated hepatic cells were long maintained to support a long-term genotype C HBV infection. (A) Fold changes of the mRNA levels of the human hepatic specific genes in hiPSC-HLCs treated with FH1 as compared to that untreated after being normalized to GAPDH ( n = 6). The primers were as shown in Supplementary Table . (B) FACS analysis for the positive ratio of the hepatic specific genes in hiPSC-HLCs treated with FH1 as compared to that untreated ( n = 6). (C) Protein levels of hALB, HBV DNA, HBsAg, and HBeAg in the supernatant, and (D) intracellular HBV RNA and cccDNA of HBV-infected hiPSC-HLCs at different time points (MOI = 200, n = 6). (E) Schematic design of the in vitro ETV, RNAi, PA452, genistein, and Myrcludex B treatments from days 10 to 20 after HBV infection. (F) Detection of relative HBV infection marker suppression of the indicated antivirals at 10 days after treatment ( n = 6). S/CO, signal-to-cutoff. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: From day 4 to 10, the functional components [1% dimethyl sulfoxide (DMSO), 10 -7 M dexamethasone (DEX, LONZA, cat # CC4182-1), 100 ng/mL hepatocyte growth factor (HGF, Sigma-Aldrich, cat # 1404), 5 μg/mL of small molecule FH1 from APExBIO (cat # BRD-K4477), 5 μg/mL insulin (LONZA, cat # CC-4321BB), 500 μM basic fibroblast growth factor (bFGF, LONZA, cat # CC4182-3), epidermal growth factor (EGF) from HCM BulletKit of LONZA (cat # CC4317BB)] were added to the medium.

Techniques: Infection, In Vitro, Marker